Biotech stocks index and XBI ETF alternative to build, weight and backtest against XBI
The biggest biotech funds disagree about what biotech means: one is a quarter four large companies, one is nearly flat across 150 small ones, one is over half diagnostics. Pick the names you actually want, set the weights, and see how the basket would have done next to XBI. Then buy it at your own broker.
Pick 2 to 10 holdings. Stocks, ETFs and crypto mix in one index.
The backtest did not run just now. Tap Backtest it to try again.
Educational only · Never places a trade
In short
A biotech stocks index is a basket of biotech companies weighted by you instead of by a fund's rule. It matters because the four big biotech ETFs hold different things. Summing every holding in the latest SEC filings, Vertex, Amgen, Gilead and Regeneron were 27.7% of IBB and 4.0% of XBI, and diagnostics and lab tools were 53.1% of ARKG but 3.7% of XBI. Indexes lets you choose the mix, backtest it against XBI and track it.
Summed from each fund's SEC N-PORT filing
What does each biotech ETF actually hold?
Every equity holding sorted into three groups. The four large profitable companies are Vertex, Amgen, Gilead and Regeneron. Diagnostics and lab tools are companies such as Illumina, Natera, 10x Genomics and Bruker that sell tests and instruments instead of drugs. Everything else is mainly drug developers. The lines are our classification, and the gaps between funds are far wider than any borderline name.
XBI
96.2% drug makers
Largest position 1.49%, ten largest 13.3%, the flattest fund here
IBB
91.5% drug makers
Vertex alone is 8.08%, ten largest 44.7%
FBT
74.3% drug makers
Thirty stocks, a quarter of them diagnostics and lab tools
ARKG
46.9% drug makers
None of the four large companies, ten largest 59.1%
XBI is the fund most people find first, with $10.73 billion and about 150 stocks. It is modified equal weight, so the largest position was 1.49% and Vertex, Amgen, Gilead and Regeneron added up to just 4.0%. If you buy XBI for biotech, you are mostly buying small and mid-sized drug developers whose value turns on trial results and takeover offers.
IBB is the opposite construction. It is weighted by company size, so Vertex was 8.08%, Amgen 7.83% and Gilead 6.84%, and the ten largest positions were 44.7% of the fund. The two funds share 41.6% of their money. FBT overlaps IBB by 40.2%, and ARKG overlaps both XBI and IBB by only about 10%. Only two companies, Natera and Veracyte, sit in all four funds, and both are diagnostics.
From each fund's SEC filing and issuer page
Which biotech ETF holds what, and what does each one cost?
| Fund | Expense ratio | Holdings | Assets | Largest positions |
|---|---|---|---|---|
| SPDR S&P Biotech (XBI) | 0.35% | 152 | $10.73 billion (June 30) | Apogee 1.49%, Moderna 1.41%, Twist 1.41%, Oruka 1.38%, Kymera 1.36% |
| iShares Biotechnology (IBB) | 0.44% | 239 | $9.09 billion (June 30) | Vertex 8.08%, Amgen 7.83%, Gilead 6.84%, Regeneron 4.91%, argenx 3.76% |
| First Trust NYSE Arca Biotechnology (FBT) | 0.55% | 30 | $2.81 billion (June 30) | Corcept 5.60%, NeoGenomics 5.12%, Veracyte 5.10%, Bruker 4.32% |
| ARK Genomic Revolution (ARKG) | 0.75% | 32 | $1.56 billion (July 31) | 10x Genomics 9.39%, Twist 7.73%, Tempus AI 6.56%, CRISPR 6.29% |
The expense ratio is charged on the whole fund, so the diagnostics you did not ask for still cost you the fee. Dividing the fee by the share in drug makers gives the yearly cost of each $100 of drug maker exposure: $0.36 for XBI, $0.48 for IBB, $0.74 for FBT and $1.60 for ARKG. That is our arithmetic, not a figure any issuer publishes. The full ranking, with cost on $10,000 and $50,000, is in the best biotech ETF article.
// The universe, five groups
Which biotech stocks can a US investor actually buy?
Nearly all of the biotech funds' holdings are US listed: 84% to 95% of each fund's equity is a US company in the filings, and the rest is mostly companies such as argenx, BeOne and Genmab that trade as US-listed ADRs or shares. Almost every name in a biotech ETF is something you can put in your own basket.
1
US listed, large profitable biotechs
2
US listed, commercial-stage mid caps
3
US listed, clinical-stage developers
4
US listed, diagnostics and lab tools
5
A fund as one line for what you do not want to pick (optional)
The builder covers Nasdaq, NYSE and NYSE American listings plus US-listed ETFs, so groups 1 to 4 go straight into an index, and group 5 lets you hold a fund as one line for the long tail of small names you do not want to pick by hand.
The first decision is the weight of the large profitable group. A size-weighted basket lets Vertex and Amgen dominate, the way IBB does, so an equal weight index or a capped one is the usual alternative. The second is how much clinical-stage risk you want: those companies can lose most of their value on one trial result, so a small, capped slice is a different bet from XBI's 92%.
From a view on biotech to a basket you can buy
How to build your own biotech stocks index in four steps
1
Decide what counts
Large profitable companies, clinical-stage developers, diagnostics and tools, or a mix? Those choices are most of the gap between IBB and ARKG.
2
Fill the groups
Search the catalog of US-listed stocks, add the companies you want, and set equal, size or your own weights with a cap.
3
Backtest against the funds
Backtest it over real market history, and build a one-line index of XBI to compare the fund with your basket.
4
Track it, then buy it
Keep the index as a named, tracked basket, then place the basket at your own broker when you are ready.
Read the maximum drawdown before the return. Biotech stocks can fall sharply on a single trial result or an FDA decision, and a concentrated basket can give back a large part of a rally. Backtests are hypothetical and past returns do not predict future ones, and a backtest can only go back as far as your youngest stock's price history, which for recent listings is short.
Three ways to own biotech stocks, compared honestly
Build your own biotech index vs a biotech ETF vs a basket broker
| Biotech ETF | Fidelity Basket Portfolios | Indexes, then your broker | |
|---|---|---|---|
| Who decides the mix of large names, developers and tools | The fund's index | You | You, and you can test it first |
| Yearly cost | 0.35% to 0.75% of the balance | $4.99 a month flat | From $24 a month for the software, billed yearly, plus your broker's cost |
| Hundreds of small names in one ticker | Yes, XBI holds about 150 and IBB about 240 | Limited to the stocks you choose | The stocks you choose, plus any fund you add as one line |
| Test the design before buying | No, you buy the fund as built | No | Yes, back to your youngest stock |
| Per-stock tax losses | No | Yes, done by you | Yes, at your broker |
| Where it falls short | You take the fund's answer on size weighting and diagnostics | No way to test a design before buying | You place and rebalance the trades yourself |
The ETF wins when you want one ticker, broad coverage of small developers and no upkeep. If that is the choice, XBI is the cheapest and IBB the most size-weighted. Building your own pays off on cost once the balance is large enough that a flat $288 a year for the software beats the fund fee, about $65,000 against IBB and $82,000 against XBI, and it pays off on control when you want a mix no fund sells.
What Indexes does and does not do: it is index construction, backtesting and tracking software. It does not hold money, place trades or give investment advice. You design and test the biotech stocks index here and hold it wherever you already invest. The same method is on the build your own ETF page, and selling a stock at a loss to swap it for a near copy is covered by the wash sale calculator.
Biotech stock questions
What people ask before they buy biotech stocks
What is the best biotech ETF?
It depends on what you want to own. XBI is the cheapest at 0.35% and the most diversified, with no position above 1.49%. IBB holds the large profitable companies, with 27.7% in Vertex, Amgen, Gilead and Regeneron. ARKG is more than half diagnostics and lab tools. FBT is a 30-stock middle ground at 0.55%.
What does the XBI ETF hold?
On June 30, 2026, XBI held about 150 stocks, led by Apogee Therapeutics at 1.49%, Moderna 1.41%, Twist Bioscience 1.41%, Oruka 1.38% and Kymera 1.36%. The ten largest were 13.3% of the fund, and Vertex, Amgen, Gilead and Regeneron together were only 4.0%, because XBI is modified equal weight.
What is the difference between XBI and IBB?
XBI is modified equal weight and IBB is weighted by company size. IBB had 44.7% in its ten largest positions against 13.3% for XBI, and 27.7% in Vertex, Amgen, Gilead and Regeneron against 4.0%. They share 41.6% of their money, so owning both is less diversification than it looks.
Is it cheaper to buy biotech stocks than a biotech ETF?
Past a certain balance, yes. A biotech ETF charges 0.35% to 0.75% of your balance every year, while a flat $288 a year for the software beats a 0.44% fee above about $65,000 and a 0.35% fee above about $82,000. The trade-off is that you place and rebalance the trades yourself.
What does ARKG hold?
On July 31, 2026, ARKG held 32 stocks led by 10x Genomics at 9.39%, Twist Bioscience 7.73%, Tempus AI 6.56%, CRISPR Therapeutics 6.29% and Personalis 5.47%. By our classification, 53.1% of it was diagnostics and lab tools, and it held none of Vertex, Amgen, Gilead or Regeneron.
How do I build my own biotech stocks index?
Decide how much goes to the large profitable names, to clinical-stage developers and to diagnostics and tools. Then set the weights with a cap on any one stock, backtest the basket against XBI, and track it. Indexes does the design, backtest and tracking, and you buy the shares at your own broker.
Sources
Holdings and net assets from each fund's latest Form N-PORT on the SEC's EDGAR database, with report dates of June 30, 2026 for XBI, IBB and FBT and July 31, 2026 for ARKG, counting equity positions only. XBI's expense ratio is from State Street's fund page and FBT's from First Trust. IBB and ARKG fees are from fund data aggregators, so confirm them on each issuer's page before you buy. The groups are our classification. Indexes is not affiliated with any fund issuer named on this page and does not give investment advice.
Build the biotech index you actually meant to buy
Choose the companies and the weights, backtest the basket against XBI, and keep it as a tracked index. Then buy it wherever you invest.